1. Home
  2. CGTL vs LSB Comparison

CGTL vs LSB Comparison

Compare CGTL & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTL
  • LSB
  • Stock Information
  • Founded
  • CGTL 2016
  • LSB 2002
  • Country
  • CGTL Hong Kong
  • LSB China
  • Employees
  • CGTL N/A
  • LSB N/A
  • Industry
  • CGTL
  • LSB
  • Sector
  • CGTL
  • LSB
  • Exchange
  • CGTL NYSE
  • LSB NYSE
  • Market Cap
  • CGTL 22.9M
  • LSB 20.4M
  • IPO Year
  • CGTL 2024
  • LSB N/A
  • Fundamental
  • Price
  • CGTL $1.02
  • LSB $1.15
  • Analyst Decision
  • CGTL
  • LSB
  • Analyst Count
  • CGTL 0
  • LSB 0
  • Target Price
  • CGTL N/A
  • LSB N/A
  • AVG Volume (30 Days)
  • CGTL 985.5K
  • LSB 858.7K
  • Earning Date
  • CGTL 08-15-2025
  • LSB 08-05-2025
  • Dividend Yield
  • CGTL N/A
  • LSB N/A
  • EPS Growth
  • CGTL 35.72
  • LSB N/A
  • EPS
  • CGTL 0.21
  • LSB N/A
  • Revenue
  • CGTL $35,611,761.00
  • LSB $79,415,311.00
  • Revenue This Year
  • CGTL N/A
  • LSB $39.33
  • Revenue Next Year
  • CGTL N/A
  • LSB $75.61
  • P/E Ratio
  • CGTL $4.76
  • LSB N/A
  • Revenue Growth
  • CGTL N/A
  • LSB N/A
  • 52 Week Low
  • CGTL $0.81
  • LSB $0.36
  • 52 Week High
  • CGTL $10.59
  • LSB $6.82
  • Technical
  • Relative Strength Index (RSI)
  • CGTL N/A
  • LSB 52.28
  • Support Level
  • CGTL N/A
  • LSB $1.02
  • Resistance Level
  • CGTL N/A
  • LSB $1.35
  • Average True Range (ATR)
  • CGTL 0.00
  • LSB 0.15
  • MACD
  • CGTL 0.00
  • LSB 0.02
  • Stochastic Oscillator
  • CGTL 0.00
  • LSB 36.54

About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED

Creative Global Technology Holdings Ltd conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.

About LSB LAKESHORE BIOPHARMA CO LTD

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Share on Social Networks: